Search Results

Now showing 1 - 1 of 1

Add to my favorites
An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas
(American Association for Cancer Research, 2002) Albar, J.P. (Juan P.); Mazzolini, G. (Guillermo); Gabari, I. (Izaskun); Melero, I. (Ignacio); Prieto, J. (Jesús); Tirapu, I. (Íñigo); Camafeita, E. (Emilio); Relloso, M. (Miguel); Schmitz, V. (Volker); Rodriguez-Calvillo, M. (Mercedes); Corbi, A.L. (Angel L.)
Monoclonal antibodies (mAbs) can mediate antitumor effects by indirect mechanisms involving antiangiogenesis and up-regulation of the cellular immune response rather than by direct tumor cell destruction. From mAbs raised by immunization of rats with transformed murine endothelial cells, a mAb (EOL4G8) was selected for its ability to eradicate a fraction of established colon carcinomas that did not express the EOL4G8-recognized antigen. The antigen was found to be ICAM-2 (CD102). Antitumor effects of EOL4G8, which required a functional T-cell compartment, were abrogated by depletion of CD8(+) cells and correlated with antitumor CTL activity, whereas only a mild inhibition of angiogenesis was observed. Interestingly, we found that EOL4G8 acting on endothelial ICAM-2 markedly enhances leukotactic factor activity-1-independent adhesion of immature dendritic cells to endothelium-an effect that is at least in part mediated by DC-SIGN (CD209).